諾力股份(603611.SH):與孚能科技簽訂2.794億元的合同
格隆匯5月18日丨諾力股份(603611.SH)公佈,近日,公司全資子公司無錫中鼎集成技術有限公司(“中鼎集成”)與孚能科技(鎮江)有限公司(“孚能科技”)簽訂了合同編號為“ZJZH20210105”的合同,合同總金額為人民幣27940萬元人民幣,中鼎集成向孚能科技提供鎮江三期電芯化成分容物流線。
上述合同的簽訂和履行,對公司當期業績不構成重大影響,對公司本年度經營業績將產生一定的積極的影響。
上述合同的簽訂有利於鞏固中鼎集成在倉儲物流系統集成業務的行業的領先地位,特別是鞏固了在新能源領域倉儲物流系統集成業務的領先地位,有利於公司加快實現向全領域智能內部物流系統提供商的轉型升級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.